期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 14, 期 28, 页码 4434-4439出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.14.4434
关键词
chemoprevention; colorectal cancer; cyclooxygenase-2; epidermal growth factor receptor; inflammatory bowel disease; mesalazine; Wnt/beta-catenin
Patients with ulcerative colitis (UC) and Crohn's disease (CD) are at increased risk for developing colorectal cancer (CRC), and this is believed to be a result of chronic inflammation. Although conclusive evidence is still missing, both epidemiological and experimental observations suggest that certain drugs used to treat inflammation, such as mesalazine, can reduce the incidence of colitis-associated CRC. Therefore, in recent years, several studies have been conducted to dissect the mechanisms by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular mechanisms that underlie the antineoplastic action of mesalazine. (C) 2008 The WJG Press. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据